Material Agreements

SOUTHERN FIRST BANCSHARES INC entered into Underwriting Agreement with Piper Sandler & Co., as representative of the several underwriters named therein valued at approximately $53.2 million (effective 2026-04-15).

“On April 15, 2026, Southern First Bancshares, Inc. (the “Company”) and its wholly owned bank subsidiary, Southern First Bank, a South Carolina state bank (the “Bank”), entered into an Underwriting Agreement (the “Underwriting Agreement”) with Piper Sandler & Co., as representative of the several underwriters named therein (the “Underwriters”), including Keefe, Bruyette & Woods, Inc., relating to the offer and sale of 1,050,000 shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”), at a public offering price of $54.00 per share in an underwritten public offering (the “Offering”).”

VerifyMe, Inc. amended Amendment (effective 2026-04-13).

“On April 15, 2026, the Parties entered into the First Amendment (the “Amendment”) to the Merger Agreement effective as of April 13, 2026, pursuant to which the outside date was extended from June 30, 2026 to August 31, 2026.”

BMW AUTO LEASING LLC entered into Underwriting Agreement with J.P. Morgan Securities LLC valued at $249,600,000; $490,200,000; $90,000,000; $580,200,000; $90,000,000 (effective 2026-04-14).

“On April 14, 2026, BMW Auto Leasing LLC (“BMW LLC”) and BMW Financial Services NA, LLC (“BMW FS”) entered into an Underwriting Agreement with J.P. Morgan Securities LLC, on behalf of itself and as a representative of the several underwriters named therein, for the sale of certain notes of BMW Vehicle Lease Trust 2026-1”

TOYOTA AUTO FINANCE RECEIVABLES LLC entered into Underwriting Agreement with Mizuho Securities USA LLC, Barclays Capital Inc., BofA Securities, Inc., SMBC Nikko Securities America, Inc. and U.S. Bancorp Investments, Inc. valued at $400,600,000; $537,900,000; $134,400,000; $672,300,000; $107,300,000; $47,500,000 (effective 2026-04-14).

“On April 14, 2026, Toyota Auto Finance Receivables LLC (“TAFR LLC”) and Toyota Motor Credit Corporation (“TMCC”) entered into an Underwriting Agreement with Mizuho Securities USA LLC, Barclays Capital Inc., BofA Securities, Inc., SMBC Nikko Securities America, Inc. and U.S. Bancorp Investments, Inc., acting on behalf of themselves and as representatives of the several underwriters named therein, for the sale of certain notes of Toyota Auto Receivables 2026-B Owner Trust, a Delaware statutory trust (the “Trust”).”

CareDx, Inc. entered into Purchase Agreement with Eurobio Scientific S.A. valued at $170 million in cash (effective 2026-04-15).

“On April 15, 2026, CareDx, Inc. (the “Company”) entered into a Purchase Agreement (the “Purchase Agreement”) with Eurobio Scientific S.A. (“Eurobio”), pursuant to which, and subject to the terms and conditions set forth therein, the Company agreed to sell to Eurobio the shares of CareDx AB, a wholly-owned Swedish subsidiary of the Company, and certain assets relating to the Company’s kitted laboratory products business and related software (the “Business”) for $170 million in cash”

LINCOLN EDUCATIONAL SERVICES CORP entered into Credit Agreement with Fifth Third Bank, National Association, Flagstar Bank, N.A., Provident Bank and Santander Bank, N.A. valued at $125 million (effective 2026-04-13).

“On April 13, 2026, Lincoln Educational Services Corporation and its subsidiaries (the “Company”) entered into an amended and restated credit agreement (the “Credit Agreement”) with the lenders referred to therein (the “Lenders”), including Fifth Third Bank, National Association, as lender and as administrative agent, joint lead arranger, and joint bookrunner (the “Agent”), and Flagstar Bank, N.A., Provident Bank and Santander Bank, N.A., as lenders and as joint lead arrangers and joint bookrunners.”

AFS SENSUB CORP. entered into Underwriting Agreement with J.P. Morgan Securities LLC (Representative), BMO Capital Markets Corp., BofA Securities, Inc., Citigroup Global Markets Inc., Lloyds Securities Inc., BNP Paribas Securities Corp., Cabrera Capital Markets, LLC, Scotia Capital (USA) Inc. and SMBC Nikko Securities America, Inc. (effective 2026-04-08).

“the Underwriting Agreement attached hereto as Exhibit 1.1 , dated as of April 8, 2026 (the “ Underwriting Agreement ”), among GM Financial, AFS SenSub and the Representative.”

ICF International, Inc. amended Amended and Restated Credit Agreement with PNC Bank, National Association as administrative agent, BOFA Securities, Inc., and Wells Fargo Securities, LLC as the joint lead arrangers valued at $600.0 million revolving credit facility (effective 2026-04-10).

“On April 10, 2026, ICF International, Inc. (the “Company” or “ICF”) and its direct, wholly owned subsidiary, ICF Consulting Group, Inc. (jointly, the “Borrowers”), entered into an Amended and Restated Credit Agreement (the “Amended and Restated Credit Agreement”) with PNC Bank, National Association as administrative agent, BOFA Securities, Inc., and Wells Fargo Securities, LLC as the joint lead arrangers, certain other financial institutions as lenders, and certain guarantors party thereto.”

AIxCrypto Holdings, Inc. amended Amended and Restated Securities Purchase Agreement with GOLD KING ARTHUR HOLDING LIMITED and Faraday Future Intelligent Electric Inc. valued at $12 million (effective 2026-04-14).

“On April 14, 2026 (the "Signing Date"), GKA and FFAI entered into an Amended and Restated Securities Purchase Agreement (the "A&R Purchase Agreement"”

AIxCrypto Holdings, Inc. amended Second Entrustment Investment Amendment Agreement with GOLD KING ARTHUR HOLDING LIMITED and Song Wang (effective 2026-04-10).

“the Company further entered into the second amendment to the entrusted agreement (the "Second Entrustment Investment Amendment Agreement")”

AIxCrypto Holdings, Inc. amended First Entrusted Investment Amendment Agreement with GOLD KING ARTHUR HOLDING LIMITED and Song Wang (effective 2026-04-10).

“On April 10, 2026, the Company, GKA, and Song entered into the first amendment to the entrusted investment agreement (the "First Entrusted Investment Amendment Agreement")”

XMax Inc. entered into Securities Purchase Agreements with twenty two non-U.S. person investors, namely Chen Yingjie, Fang Chongyi, Jiang Yan, Ma Ying, Ren Guangfei, Ren Tao, Shen Xiaoyan, Song Rongrong, Tan Kaichang, Tang Min, Wang Haifeng, Wang Jinhua, Wang Li, Wang Zecui, Wei Huifen, Yao Jing, Yu Suying, Zeng Qingyu, Zhang Bingli, Zhang Ciqiang, Zhao Xia valued at aggregate offering price of $3,101,062.50 (effective 2026-04-13).

“On April 13, 2026, XMax Inc. (the “ Company ”) entered into Securities Purchase Agreements (the “ Agreements ”) with twenty two non-U.S. person investors, namely Chen Yingjie, Fang Chongyi, Jiang Yan, Ma Ying, Ren Guangfei, Ren Tao, Shen Xiaoyan, Song Rongrong, Tan Kaichang, Tang Min, Wang Haifeng, Wang Jinhua, Wang Li, Wang Zecui, Wei Huifen, Yao Jing, Yu Suying, Zeng Qingyu, Zhang Bingli, Zhang Ciqiang, Zhao Xianxian and Zhao Zheyao (the “ Purchasers ”), pursuant to which the Company agreed to sell to the Purchasers in a private placement for a total of 462,500 shares (the “ Shares ”) of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), at a purchase price of $6.705 per share for an aggregate offering price of $3,101,062.50 (the “ Private Placement ”).”

NightFood Holdings, Inc. entered into Supply Agreement with NUWA Robotics Corp. and Hon Hai Precision Industry Co., Ltd. (effective 2026-04-11).

“On April 11, 2026, TechForce Robotics, Inc. ("TechForce" or "Collaborator"), a wholly-owned subsidiary of Nightfood Holdings, Inc. (the "Company"), entered into a Supply Agreement (the "Agreement") with NUWA Robotics Corp. (the "Purchaser") and Hon Hai Precision Industry Co., Ltd., ("HH").”

Evofem Biosciences, Inc. amended Fourth Amendment with Adjuvant Global Health Technology Fund, L.P. and Adjuvant Global Health Technology Fund DE, L.P. (together, Adjuvant) (effective 2026-04-10).

“On April 10, 2026 (the “Effective Date”), Evofem Biosciences, Inc. (the “Company”), Adjuvant Global Health Technology Fund, L.P., and Adjuvant Global Health Technology Fund DE, L.P. (together, “Adjuvant”) entered into a fourth amendment (the “Fourth Amendment”) to the Securities Purchase Agreement dated as of October 14, 2020, as amended, pursuant to which Adjuvant purchased from the Company certain convertible promissory notes (the “Notes”).”

Spyre Therapeutics, Inc. entered into Underwriting Agreement with Jefferies LLC, Goldman Sachs & Co. LLC, Evercore Group L.L.C. and Guggenheim Securities, LLC, as the representatives of the underwriters valued at approximately $463.5 million (effective 2026-04-14).

“The Underwriting Agreement contains customary representations and warranties, agreements and obligations, conditions to closing and termination provisions.”

Blue Owl Capital Corp entered into Tenth Supplemental Indenture with Deutsche Bank Trust Company Americas valued at $400,000,000 aggregate principal amount (effective 2026-04-16).

“On April 16, 2026, Blue Owl Capital Corporation (the “Company”) and Deutsche Bank Trust Company Americas (the “Trustee”), entered into a Tenth Supplemental Indenture (the “Tenth Supplemental Indenture”) to the Indenture, dated as of April 10, 2019, between the Company and the Trustee (the “Base Indenture”, and together with the Tenth Supplemental Indenture, the “Indenture”), relating to the Company’s $400,000,000 aggregate principal amount of its 6.450% notes due 2028 (the “Notes”).”

Versus Systems Inc. entered into Stock Purchase Agreement with ASPIS Cyber Technologies, Inc. valued at $1,700,000 (effective 2026-04-15).

“On April 15, 2026, Versus Systems, Inc. (the “Company”) and ASPIS Cyber Technologies, Inc. (“ASPIS”) entered into a Stock Purchase Agreement (the “SPA”).”

MeiraGTx Holdings plc terminated Original Asset Purchase Agreement with Janssen Pharmaceuticals, Inc. (effective 2026-04-15).

“Seller and Buyer entered into a Termination Agreement on April 15, 2026 (the “Termination Agreement”) terminating that certain Asset Purchase Agreement, dated as of December 20, 2023 (the “Original Asset Purchase Agreement”), by and among Seller and the Company and its wholly-owned subsidiary MeiraGTx UK II Limited, a company incorporated in England and Wales (“MeiraGTx UK II”), that certain Supply Agreement, dated as of December 20, 2023 by and between MeiraGTx UK II and Seller, and certain other documents related to the Original Asset Purchase Agreement.”

MeiraGTx Holdings plc entered into Asset Purchase Agreement with Janssen Pharmaceuticals, Inc. valued at $25,000,000 (effective 2026-04-15).

“On April 15, 2026 (the “Closing Date”), MeiraGTx Holdings plc (the “Company”) and its wholly-owned subsidiary MeiraGTx Ocular UK Limited, a company incorporated in England and Wales (“MeiraGTx Ocular” and together with the Company, collectively the “Buyer”), entered into and consummated an Asset Purchase Agreement (the “Asset Purchase Agreement”) with Janssen Pharmaceuticals, Inc., a Pennsylvania corporation (“Seller”), pursuant to which Seller sold and assigned to Buyer, and Buyer purchased and assumed, that certain License Agreement, dated February 5, 2019, by and between UCL Business Plc (now UCL Business Ltd.) and Janssen (the “UCL License Agreement”), relating to the research, development, manufacture and exploitation of Seller’s gene therapy product for the treatment of X-linked retinitis pigmentosa related to mutations in the RPGR gene (the “RPGR Product”), and other related assets as described in the Asset Purchase Agreement. Buyer agreed to pay an upfront cash purchase price o”

MeiraGTx Holdings plc entered into Underwriting Agreement with BofA Securities, Inc. and Goldman Sachs & Co. LLC valued at approximately $93.3 million (effective 2026-04-16).

“On April 16, 2026, MeiraGTx Holdings plc (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with BofA Securities, Inc. and Goldman Sachs & Co. LLC (the “Underwriters”), in connection with the issuance and sale by the Company in an offering of 11,111,111 ordinary shares of the Company (the “Shares”) at an offering price of $9.00 per share, less underwriting discounts and commissions”

Acurx Pharmaceuticals, Inc. entered into Securities Purchase Agreement with the investors named therein (the "Investors") valued at aggregate gross proceeds of approximately $2.5 million (effective 2026-04-15).

“On April 15, 2026, Acurx Pharmaceuticals, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the investors named therein (the “Investors”), pursuant to which the Company agreed to issue and sell, in a registered direct offering by the Company directly to the Investors (the “Registered Offering”) (i) 816,068 shares (the “Shares”) of common stock, par value $0.001 per share, of the Company (the “Common Stock”) at a purchase price of $3.03 per share and (ii) pre-funded common stock purchase warrants (the “Pre-Funded Warrants”) to purchase up to 9,017 shares of Common Stock (the “Pre-Funded Warrant Shares”) at a purchase price of $3.029 per share for aggregate gross proceeds of approximately $2.5 million”

HeartBeam, Inc. entered into Underwriting Agreement with Titan Partners Group LLC, a division of American Capital Partners, LLC valued at approximately $10.0 million (effective 2026-04-14).

“On April 14, 2026, HeartBeam, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Titan Partners Group LLC, a division of American Capital Partners, LLC (the “Underwriter”), pursuant to which the Company agreed to issue and sell in an underwritten public offering (the “Offering”) an aggregate of 12,500,000 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (“Common Stock”).”

Momentus Inc. entered into Placement Agency Agreement with A.G.P./Alliance Global Partners valued at 7.0% of the aggregate gross proceeds (effective 2026-04-14).

“In connection with the private placement, on April 14, 2026, the Company entered into a Placement Agency Agreement with the Placement Agent.”

Momentus Inc. entered into Registration Rights Agreement with an institutional investor (effective 2026-04-14).

“In connection with the private placement, the Company entered into a Registration Rights Agreement with the Investor (the “Registration Rights Agreement”) requiring the Company to file a registration statement covering the resale of all of the Registrable Securities (as defined in the Registration Rights Agreement) with the Securities and Exchange Commission (the “SEC”) no later than the 7th trading day following the date of the Registration Rights Agreement”

Momentus Inc. entered into Securities Purchase Agreement with an institutional investor valued at approximately $5 million (effective 2026-04-14).

“On April 14, 2026, Momentus Inc., a Delaware corporation (“Momentus” or the “Company”), entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with an institutional investor (the “Investor”) for a private placement of (i) 450,000 shares of the Company’s Class A common stock, par value $0.00001 per share (the “Common Stock”), for $3.75 per share and (ii) pre-funded warrants to purchase up to 883,334 shares of Common Stock (the “Pre-Funded Warrants” and, together with the Common Stock, the “Securities”).”

Katapult Holdings, Inc. amended Tenth Limited Waiver with Midtown Madison Management LLC (effective 2026-04-15).

“On April 15, 2026, Katapult Holdings, Inc. (the “Company”) entered into the Limited Waiver (the “Tenth Limited Waiver”) to our Amended and Restated Loan and Security Agreement”

FARADAY FUTURE INTELLIGENT ELECTRIC INC. amended Amended and Restated Securities Purchase Agreement with the Investor (effective 2026-04-14).

“On April 14, 2026 (the “Signing Date”), the Company and the Investor entered into an Amended and Restated Securities Purchase Agreement (the “A&R Purchase Agreement”, and collectively with Purchase Agreement, the “SPA”).”

FARADAY FUTURE INTELLIGENT ELECTRIC INC. entered into Loan Agreement with an accredited investor valued at $2,000,000 (effective 2026-04-10).

“On April 10, 2026, Faraday Future Intelligent Electric Inc. (the “Company”) entered into a loan agreement (the “Loan Agreement”) an accredited investor (the “Investor”), pursuant to which, the Company borrowed, and the Investor lent the Company an aggregate of $2,000,000 with the interest accruing at a rate of 10% per annum (the “Loan Amount”).”

OppFi Inc. terminated total return swaps with affiliates of Midtown (effective 2026-04-15).

“On April 15, 2026 (the “Gray Rock Termination Date”), OppFi-LLC terminated those certain total return swaps (the “TRS”) previously entered into on April 15, 2022 with affiliates of Midtown”

OppFi Inc. amended Third Amendment to Second Amended and Restated Revolving Credit Agreement with Midtown Madison Management LLC (effective 2026-04-10).

“and the lenders party thereto entered into a Third Amendment to Second Amended and Restated Revolving Credit Agreement (the “Third Amendment”), which amended that certain Second Amended and Restated Revolving Credit Agreement”

Franklin BSP Capital Corp amended Amendment No. 5 with Wells Fargo Bank, National Association, U.S. Bank National Association, U.S. Bank Trust Company, National Association valued at $400,000,000 (effective 2026-04-10).

“On April 10, 2026, FBLC Funding I, LLC (the “Subsidiary”), a wholly-owned, special purpose financing subsidiary of Franklin BSP Capital Corporation (the “Corporation”) entered into Amendment No. 5 (together with any documents executed in connection therewith, “Amendment No. 5”) to that certain loan and servicing agreement (as amended and together with any other documents executed in connection therewith, the “Amended Credit Facility”; capitalized terms used and not otherwise defined herein shall have the meanings given to such terms in the Amended Credit Facility), initially entered into as of August 28, 2020, by and among the Corporation, the Subsidiary, Wells Fargo Bank, National Association, as administrative agent and lender, U.S. Bank National Association as collateral custodian and U.S. Bank Trust Company, National Association, as collateral agent.”

Onfolio Holdings, Inc amended Limited Waiver and Amendment Agreement with the Holder (effective 2026-04-10).

“On April 10, 2026, the Company entered into a Limited Waiver and Amendment Agreement with the Holder (the “ Waiver Agreement ”). The Waiver Agreement provides for specific waivers and forbearances related to existing”

Onfolio Holdings, Inc entered into Registration Rights Agreement with a certain institutional investor (effective 2026-04-10).

“in connection with the Purchase Agreement, also on April 10, 2026, the Company entered into a Registration Rights Agreement (the “ Registration Rights Agreement ”) with the Investor, pursuant to which the Company agreed to file and maintain a registration statement (the “ Registration Statement ”) registering the resale of the shares of Common Stock issuable pursuant to the Purchase Agreement”

Onfolio Holdings, Inc entered into Equity Purchase Facility Agreement with a certain institutional investor valued at up to an aggregate of $100 million (effective 2026-04-10).

“On April 10, 2026, Onfolio Holdings Inc. (the “ Company ”) entered into an Equity Purchase Facility Agreement (the “ Purchase Agreement ”) with a certain institutional investor (the “ Investor ”). Pursuant to the Purchase Agreement, the Company has the right, but not the obligation, to sell to the Investor, from time to time and in the Company’s sole discretion, up to an aggregate of $100 million of newly issued shares of the Company’s common stock”

Aspire Biopharma Holdings, Inc. entered into Securities Purchase Agreement with certain accredited investors (effective 2026-02-06).

“on February 6, 2026, Aspire Biopharma Holdings, Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Securities Purchase Agreement ”) with certain accredited investors (the “ Investors ”)”

1606 CORP. amended First Amendment to Purchase and Sale Agreement with Jefferson Enterprise Energy, LLC (effective 2026-04-13).

“On April 13, 2026, 1606 Corp., a Nevada corporation (the " Company "), and Jefferson Enterprise Energy, LLC, a Texas limited liability company (" Seller "), entered into the First Amendment to Purchase and Sale Agreement (the " First Amendment "), amending that certain Purchase and Sale Agreement effective as of March 12, 2026 (the " Agreement "), relating to the Company's purchase of certain real property and related assets located in Angelina County, Texas.”

Lumen Technologies, Inc. entered into Credit Agreement with Bank of America, N.A. valued at $825 million (effective 2026-04-14).

“entered into the Revolving Credit Agreement (the “Credit Agreement”) providing for a revolving credit facility with commitments of $825 million.”

CHEETAH NET SUPPLY CHAIN SERVICE INC. entered into Share Transfer Agreement with Leyan Yang valued at approximately $4.98 million (effective 2026-04-16).

“On April 16, 2026 Cheetah Net Supply Chain Service Inc., a Delaware corporation (the "Transferee" or the "Company"), entered into a Share Transfer Agreement (the "Share Transfer Agreement") with Leyan Yang, a non-U.S. individual (the "Transferor"), pursuant to which the Transferee agreed to acquire from the Transferor 100% of the issued shares of Super International Trading Limited”

John Hancock Comvest Private Income Fund amended Fifth Amendment with Sumitomo Mitsui Banking Corporation, as collateral agent, administrative agent, and a lender and Webster Bank, N.A., as a lender valued at $400 million credit facility, which allows the Borrower to borrow up to $445 million (effective 2026-04-14).

“On April 14, 2026, Comvest Senior Lending Fund LL1 SPV, LLC (the “ Borrower ”), a Delaware limited liability company and subsidiary of John Hancock Comvest Private Income Fund, a Delaware statutory trust (the “ Fund ”), entered into a Fifth Amendment to that certain Loan and Servicing Agreement dated as of July 16, 2024 (the “ Fifth Amendment ”).”

Audax Private Credit Fund, LLC entered into Senior Secured Credit Agreement with JPMorgan Chase Bank, N.A., PNC Bank, National Association and Pinnacle Bank, a Tennessee bank, d/b/a Synovus Bank valued at $275,000,000 (effective 2026-04-10).

“On April 10, 2026, Audax Private Credit Fund, LLC (the “ Fund ”), as borrower, entered into a senior secured credit facility (the “ Facility ”) pursuant to a Senior Secured Credit Agreement (the “ Agreement ”; capitalized terms used but not defined herein shall have the meanings specified in the Agreement), with JPMorgan Chase Bank, N.A., as administrative agent and as collateral agent, the lenders party thereto (the “ Lenders ”), and JPMorgan Chase Bank, N.A., PNC Bank, National Association and Pinnacle Bank, a Tennessee bank, d/b/a Synovus Bank, as lead arrangers and bookrunners.”

Smart Powerr Corp. entered into Purchase Agreement with Streeterville Capital, LLC valued at $1,050,000 (effective 2026-04-10).

“On April 10, 2026, Smart Powerr Corp., a Nevada corporation (the “Company”) entered into a note purchase agreement (the “Purchase Agreement”) with Streeterville Capital, LLC, a Utah limited liability company (“Lender”) pursuant to which the Company issued and sold to the Lender a secured promissory note in the original principal amount of $1,050,000 (the “A-1 Note”).”

Capstone Holding Corp. amended Conversion Price Voluntary Adjustment Notice with institutional investor valued at reduction of conversion price to $0.57 for $500,000 of principal amount (effective 2026-04-16).

“On that date, pursuant to Section 7(h) of the October 2025 Convertible Note, the Company and the Buyer agreed, pursuant to a Conversion Price Voluntary Adjustment Notice signed by both parties, to reduce the Conversion Price to $0.57 with regard to $500,000 of the principal amount that previously had a $1.10 conversion price.”

PENN Entertainment, Inc. amended Amendment with Bank of America, N.A valued at $1.0 billion revolving credit facility and $446.9 million term loan A facility (effective 2026-04-16).

“On April 16, 2026, PENN Entertainment, Inc. (the “Company”) entered into an amendment (the “Amendment”) to its Second Amended and Restated Credit Agreement, dated as of May 3, 2022”

ACHIEVE LIFE SCIENCES, INC. entered into Securities Purchase Agreement with certain institutional and accredited investors valued at approximately $180.0 million (effective 2026-04-15).

“On April 15, 2026, Achieve Life Sciences, Inc. (the “Company”), entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional and accredited investors (the “Investors”), pursuant to which the Company agreed to sell and issue to the Investors in a private placement (the “Private Placement”) an aggregate of (i) 49,418,069 shares (the “Shares”) of the Company’s common stock”

SPIRE INC entered into Membership Interest Purchase Agreement with Subterra Energy Holdings, LLC valued at $600 million.

“On April 14, Spire Midstream LLC, a Missouri limited liability company and wholly-owned subsidiary of Spire Inc. (the “Seller”), and Subterra Energy Holdings, LLC, a Delaware limited liability company (the “Buyer”) (collectively the “Parties”), entered into a Membership Interest Purchase Agreement (the “Agreement”), pursuant to which the Seller has agreed to sell to the Buyer all of the issued and outstanding membership interests of Belle Butte LLC, a Missouri limited liability company (“Company”), for cash purchase price equal to $600 million payable at the closing and $50 million deferred consideration payable on or before September 2027, subject to customary adjustments as set forth in the Agreement (the “Transaction”) and the other terms and conditions of the Agreement.”

Traws Pharma, Inc. entered into Purchase Agreement with the purchasers named therein valued at approximately $10,000,000 (effective 2026-04-15).

“On April 15, 2026, Traws Pharma, Inc. (the “Company”) announced the pricing of an offering (the “Private Placement”) of an aggregate of (i) 5,982,919 shares (the “Purchased Shares”) of the Company’s common stock, par value $0.01 per share (“Common Stock”) (or, in lieu of Purchased Shares, pre-funded warrants to purchase shares of Common Stock (“Pre-Funded Warrants”)), (ii) Series A warrants to initially purchase up to 5,982,919 shares of Common Stock (the “Series A Warrants”), (iii) Series B warrants to initially purchase up to 5,982,919 shares of Common Stock (the “Series B Warrants”), and (iv) Series C warrants to initially purchase up to 17,948,757 shares of Common Stock (the “Series C Warrants” and together with the Pre-Funded Warrants, the Series A Warrants and the Series B Warrants, the “Warrants”) pursuant to a Securities Purchase Agreement (the “Purchase Agreement”) by and between the Company and the purchasers named therein (the “Investors”).”

MARCHEX INC entered into Settlement Agreement valued at $750,000 (and agree to the release of $250,000 held in escrow by U.S. Bank) (effective 2026-04-14).

“On April 14, 2026, the Company entered into a Settlement Agreement (the “Agreement”) with respect to this civil action for such expected settlement amount, which resolves all claims related to this matter.”

HYUNDAI ABS FUNDING LLC terminated Omnibus Distribution and Termination Agreement with Hyundai Capital America, Hyundai ABS Funding, LLC, Hyundai Auto Receivables Trust 2022-A, Citibank, N.A., U.S. Bank Trust National Association (effective 2026-04-09).

“On April 9, 2026, Hyundai Capital America (“ HCA ”), Hyundai ABS Funding, LLC (the “ Depositor ”), Hyundai Auto Receivables Trust 2022-A (the “ Issuing Entity ”), Citibank, N.A., as indenture trustee (the “ Indenture Trustee ”), and U.S. Bank Trust National Association, as owner trustee (the “ Owner Trustee ”) entered into an Omnibus Distribution and Termination Agreement, with the consent of HCA and the Depositor, as owners of 100% of the certificates and all classes of notes that remain outstanding.”

Stereotaxis, Inc. entered into Share Sale Agreement with Robocath, the Sellers, and the Manager valued at $20.0 million (effective 2026-04-14).

“On April 14, 2026, Stereotaxis, Inc. (“Stereotaxis” or the “Company”) entered into a Share Sale Agreement with Robocath, a French société par actions simplifiée , (“Robocath”), the shareholders of Robocath party thereto (the “Sellers”) and an individual serving as manager (the “Manager”) to acquire (the “Acquisition”) shares and other securities collectively representing 100% of the share capital and voting power of Robocath (on a fully-diluted basis) (the “Robocath Securities”) from the Sellers.”

Leidos Holdings, Inc. entered into Contribution and Equity Purchase Agreement with Altaris, LLC valued at Leidos Inc. contributes SES/IA Business to JV for 41.5% equity; AHP Entities contribute Analogic Hol (effective 2026-04-14).

“On April 14, 2026, Leidos, Inc. (“ Leidos Inc. ”), a Delaware corporation and a wholly-owned subsidiary of Leidos Holdings, Inc. (“ Leidos ”), entered into a Contribution and Equity Purchase Agreement (the “ Contribution Agreement ”), together with Leidos solely for certain limited purposes set forth therein, with certain affiliates of Altaris, LLC, a Delaware limited liability company (“ Altaris ,” and such affiliates, the “ AHP Entities ”), to form a new joint venture (the “ JV ”) combining the Security Enterprise Solutions and the Industrial Automation businesses of Leidos (together, the “ SES/IA Business ”) with Analogic Corporation (“ Analogic ”), a portfolio company of Altaris.”